Literature DB >> 15847667

Reticulated platelets: a reliable measure to reduce prophylactic platelet transfusions after intensive chemotherapy.

Driss Chaoui1, Tahar Chakroun, Françoise Robert, Bernard Rio, Ramdane Belhocine, Ollivier Legrand, Celia Salanoubat, Chantal Lecrubier, Nicole Casadevall, Jean-Pierre Marie, Ismail Elalamy.   

Abstract

BACKGROUND: Reticulated platelets (RPs) are the youngest circulating platelets (PLTs). The aim of our study was to predict PLT recovery with RP percentage (RP%) and therefore to identify PLT transfusions that could be avoided after autologous peripheral blood progenitor cell (PBPC) transplantation. STUDY DESIGN AND METHODS: With a whole-blood dual-labeling flow cytometric method, RP% was prospectively assessed in 47 patients who received myeloablative chemotherapy followed by autologous PBPC transplantation. Retrospective analysis of RP evolution identified three time points: nadir of the RP% (NRP), imminent PLT recovery (IPR) corresponding to an RP% of greater than 7 percent, and PLT transfusion autonomy (PTA).
RESULTS: Median occurrences of NRP, IPR, and PTA were on Days +5, +8, and +12 after transplantation, respectively. The RP% value at NRP (4%) was significantly lower compared to the IPR (15%) and PTA (14%). Thirty patients (64%) achieved PTA within 4 days after IPR. On Day +8, if RP% was greater than 7 percent, positive and negative predictive values for PTA within 4 days, specificity, and sensitivity were 79, 63, 66, and 76 percent, respectively. Fever between IPR and PTA was the only factor found to negatively influence PLT recovery (p = 0.02). All patients required at least one PLT transfusion. Among patients with rapid PLT recovery (IPR-PTA interval < 4 days; n = 30), half of them received one PLT transfusion after RP increase, which could be avoided.
CONCLUSION: These encouraging results may allow us to reduce the prophylactic PLT transfusion according to patients RP% increase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15847667     DOI: 10.1111/j.1537-2995.2005.04286.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

Review 1.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon J Stanworth; Carolyn Doree; Sally Hopewell; Marialena Trivella; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-11-18

Review 2.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Gemma L Crighton; Lise J Estcourt; Erica M Wood; Marialena Trivella; Carolyn Doree; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

Review 3.  Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Patricia Blanco; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-10-27

4.  Immature platelet fraction measured on the Sysmex XN hemocytometer predicts thrombopoietic recovery after autologous stem cell transplantation.

Authors:  Noreen van der Linden; Lieke J J Klinkenberg; Steven J R Meex; Erik A M Beckers; Norbert C J de Wit; Lenneke Prinzen
Journal:  Eur J Haematol       Date:  2014-04-25       Impact factor: 2.997

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.